Stephenson Judith J, Wertz Debra, Gu Tao, Patel Jeetvan, Dalal Anand A
HealthCore, Inc., Wilmington, DE.
GlaxoSmithKline, Research Triangle Park, NC, USA.
Int J Chron Obstruct Pulmon Dis. 2017 Jul 4;12:1947-1959. doi: 10.2147/COPD.S134618. eCollection 2017.
The degree to which symptoms such as dyspnea affect patients with COPD is individualized. To address the gap between clinical symptom measures and self-perceived disease burden, we investigated the symptom status of adult patients with COPD and followed with an administrative claims analysis of health care resource utilization and costs.
This was a hybrid US observational study consisting of a cross-sectional patient survey followed by a retrospective analysis of administrative claims data. The primary COPD symptom measures were the modified Medical Research Council (mMRC) Dyspnea scale and the COPD Assessment Test (CAT).
A total of 673 patients completed the survey. Of these, 65% reported mMRC grades 0-1 (low symptomatology) and 35% reported mMRC grades 2-4 (high symptomatology); 25% reported CAT score <10 (low symptomatology) and 75% reported CAT score ≥10 (high symptomatology). More patients with high symptomatology (by either measure) had at least one COPD-related inpatient hospitalization, emergency room visit, physician office visit, or other outpatient services, and filled at least one COPD-related prescription medication vs patients with low symptomatology. COPD-related costs were higher for patients with high symptomatology than patients with low symptomatology. In a multivariate analysis, COPD-related costs were also higher in patients reporting severe symptoms.
Patients with high COPD symptomatology utilized more health care resources and had higher COPD-related health care costs during the 6-month post-survey period than patients with low symptomatology.
诸如呼吸困难等症状对慢性阻塞性肺疾病(COPD)患者的影响程度因人而异。为了弥合临床症状测量与自我感知的疾病负担之间的差距,我们调查了成年COPD患者的症状状况,并随后对医疗资源利用和成本进行了行政索赔分析。
这是一项美国混合观察性研究,包括横断面患者调查以及对行政索赔数据的回顾性分析。主要的COPD症状测量指标是改良的医学研究委员会(mMRC)呼吸困难量表和COPD评估测试(CAT)。
共有673名患者完成了调查。其中,65%报告mMRC分级为0 - 1级(症状较轻),35%报告mMRC分级为2 - 4级(症状较重);25%报告CAT评分<10分(症状较轻),75%报告CAT评分≥10分(症状较重)。与症状较轻的患者相比,症状较重的患者(通过任何一种测量方法)有更多人至少有一次与COPD相关的住院治疗、急诊就诊、医生门诊就诊或其他门诊服务,并且至少开具了一种与COPD相关的处方药。症状较重患者的COPD相关成本高于症状较轻的患者。在多变量分析中,报告有严重症状的患者的COPD相关成本也更高。
与症状较轻的患者相比,症状较重的COPD患者在调查后的6个月期间使用了更多的医疗资源,且COPD相关医疗成本更高。